Reversal of ABCG2-mediated multidrug resistance by human cathelicidin and its analogs in cancer cells

Peptides

Volumn 40, Issue , 2013, Pages 13-21

  To, Kenneth K W ^a   Ren, S X ^a   Wong, C C M ^a   Cho, Chi Hin ^a  

^a Prince of Wales Hospital   (Hong Kong)

Author keywords

ABCG2; Cathelicidin LL37; Efflux transporter; Host defense peptides; Multidrug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CATHELICIDIN LL13 37; CATHELICIDIN LL17 32; LL 13 37; LL 17 32; MITOXANTRONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; HOST RESISTANCE; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOXANTRONE; NEOPLASM PROTEINS; PEPTIDES; PROTEOLYSIS;

EID: 84872112005     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2012.12.019     Document Type: Article

References (38)

1. J.D. Allen, A. van Loevezijn, J.M. Lakhai, M. van der Valk, O. van Tellingen, and G. Reid Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C Mol Cancer Res 1 2002 417 425
2. S.V. Ambudkar Drug-stimulated ATPase activity in crude membranes of human MDR1-transfected mammalian cells Methods Enzymol 292 1998 504 514
3. Y. An, and W.M. Ongkeko ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol 5 2009 1529 1542
4. R. Clark, I.D. Kerr, and R. Callaghan Multiple drug binding sites on the R482G isoform of the ABCG2 transporter Br J Pharmacol 149 2006 506 515
5. M. Falasca, and K.J. Linton Investigational ABC transporter inhibitors Expert Opin Investig Drugs 21 2012 657 666
6. Y.A. Gandhi, and M.E. Morris Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2) AAPS J 11 2009 541 552
7. N. Giri, S. Agarwal, N. Shaik, G. Pan, Y. Chen, and W.F. Elmquist Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design Drug Metab Dispos 37 2009 560 570
8. H. Glavinas, E. Kis, A. Pal, R. Kovacs, M. Jani, and E. Vagi ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions Drug Metab Dispos 35 2007 1533 1542
9. S.A. Johnstone, K. Gelmon, L.D. Mayer, R.E. Hancock, and M.B. Bally In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines Anticancer Drug Des 15 2000 151 160
10. G.M. Lai, Y.N. Chen, L.A. Mickley, A.T. Fojo, and S.E. Bates P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines Int J Cancer 49 1991 696 703
11. G.D. Leonard, T. Fojo, and S.E. Bates The role of ABC transporters in clinical practice Oncologist 8 2003 411 424
12. X. Li, Y. Li, H. Han, D.W. Miller, and G. Wang Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region J Am Chem Soc 128 2006 5776 5785
13. B. Ma, S. Chai, N. Li, K.K. To, W.L. Kan, and D. Yang Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic α-aminoxy peptidomimetic Int J Pharm 424 2012 33 39
14. M.H. Metz-Boutigue, P. Shooshtarizadeh, G. Prevost, Y. Haikel, and J.F. Chich Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules Curr Pharm Des 16 2010 1024 1039
15. Y.J. Mi, Y.J. Liang, H.B. Huang, H.Y. Zhao, C.P. Wu, and F. Wang Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters Cancer Res 70 2010 7981 7991
16. C. Ozvegy-Laczka, G. Varady, G. Koblos, O. Ujhelly, J. Cervenak, and J.D. Schuetz Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface J Biol Chem 280 2005 4219 4227
17. H. Peng, Z. Dong, J. Qi, Y. Yang, Y. Liu, and Z. Li A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy PLoS ONE 4 2009 e5676
18. A. Pick, H. Muller, and M. Wiese Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2) Bioorg Med Chem 16 2008 8224 8236
19. M.H. Raaijmakers, E.P. de Grouw, L.H. Heuver, B.A. van der Reijden, J.H. Jansen, and R.J. Scheper Breast cancer resistance protein in drug resistance of primitive CD34+38-cells in acute myeloid leukemia Clin Cancer Res 11 2005 2436 2444
20. A. Risso Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity J Leukoc Biol 68 2000 785 792
21. R.W. Robey, W.Y. Medina-Perez, K. Nishiyama, T. Lahusen, K. Miyake, and T. Litman Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells Clin Cancer Res 7 2001 145 152
22. R.W. Robey, O. Polgar, J. Deeken, K.W. To, and S.E. Bates ABCG2: determining its relevance in clinical drug resistance Cancer Metastasis Rev 26 2007 39 57
23. R.W. Robey, K. Steadman, O. Polgar, K. Morisaki, M. Blayney, and P. Mistry Pheophorbide A is a specific probe for ABCG2 function and inhibition Cancer Res 64 2004 1242 1246
24. B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system Physiol Rev 86 2006 1179 1236
25. E. Schneider, J.K. Horton, C.H. Yang, M. Nakagawa, and K.H. Cowan Multidrug resistance-associated protein gene overexpression and reduced drug senstivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance Cancer Res 54 1994 152 158
26. K. Shiozawa, M. Oka, H. Soda, M. Yoshikawa, Y. Ikegami, and J. Tsurutani Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic Int J Cancer 108 2004 146 151
27. P. Skehan, R. Stornet, D. Scudiero, A. Monks, J. McMahon, and D. Vistica New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 1990 1107 1112
28. A. Telbisz, C. Hegedus, C. Ozvegy-Laczka, K. Goda, G. Varady, and Z. Takats Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter Eur J Pharm Sci 45 2012 101 109
29. K.K. To, R. Robey, Z. Zhan, L. Bangiolo, and S.E. Bates Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway Mol Cancer Res 9 2011 516 527
30. M.L. Vlaming, J.S. Lagas, and A.H. Schinkel Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice Adv Drug Deliv Rev 61 2009 14 25
31. K. Wakabayashi, H. Nakagawa, A. Tamura, S. Koshiba, K. Hoshijima, and M. Komada Intramolecular disulphide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein J Biol Chem 282 2007 27841 27846
32. J.H. Wong, A. Legowska, K. Rolka, T.B. Ng, M. Hui, and C.H. Cho Effects of cathelicidin and its fragments on three key enzymes of HIV-1 Peptides 32 2011 1117 1122
33. C.C.W. Wong, L. Zhang, Z.J. Li, W.K.K. Wu, S.X. Ren, and Y.C. Chen Protective effects of cathelicidin-encoding Lactococcus lactis in murine ulcerative colitis J Gastroent Hepat 27 2012 1205 1212
34. C.P. Wu, A.M. Calcagno, and S.V. Ambudkar Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies Curr Mol Pharmacol 1 2008 93 105
35. W.K.K. Wu, J.J.Y. Sung, K.F. To, L. Yu, K.M. Chu, and J. Yu The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells J Cell Physiol 223 2010 178 186
36. W.K. Wu, G. Wang, S.B. Coffelt, A.M. Betancourt, C.W. Lee, and D. Fan Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications Int J Cancer 27 2010 1741 1747
37. Y.H. Yang, W.K.K. Wu, E.K.K. Tai, H.P.S. Wong, E.K.Y. Lam, and V.Y. Shin The cationic host defense peptide rCRAMP promotes gastric ulcer healing in rats J Pharmacol Exp Ther 318 2006 547 554
38. K. Yamasaki, J. Schauber, A. Coda, H. Lin, R.A. Dorschner, and N.M. Schechter Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin FASEB J 20 2006 2068 2080